Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Globe Newswire (Tue, 3-Mar 4:15 PM ET)
Globe Newswire (Tue, 3-Mar 4:15 PM ET)
Globe Newswire (Tue, 3-Mar 7:00 AM ET)
Market Chameleon (Fri, 6-Feb 6:10 AM ET)
Market Chameleon (Fri, 6-Feb 2:56 AM ET)
Globe Newswire (Fri, 6-Feb 7:00 AM ET)
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
Globe Newswire (Fri, 6-Feb 7:00 AM ET)
Globe Newswire (Fri, 6-Feb 7:00 AM ET)
Globe Newswire (Fri, 23-Jan 5:25 PM ET)
Globe Newswire (Fri, 23-Jan 4:15 PM ET)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.
As of March 25, 2026, ROIV stock price climbed to $27.45 with 1,705,987 million shares trading.
ROIV has a beta of 0.79, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.17 to the broad based SPY ETF.
ROIV has a market cap of $19.65 billion. This is considered a Large Cap stock.
Last quarter Roivant Sciences Ltd. - Common Shares reported $2 million in Revenue and -$.24 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.10.
In the last 3 years, ROIV traded as high as $30.33 and as low as $6.92.
The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
ROIV has outperformed the market in the last year with a return of +153.5%, while the SPY ETF gained +15.8%. In the last 3 month period, ROIV beat the market returning +22.0%, while SPY returned -4.6%. However, in the most recent 2 weeks ROIV has underperformed the stock market by returning -7.6%, while SPY returned -2.7%.
ROIV support price is $26.22 and resistance is $27.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.
